Literature DB >> 10843721

A self MHC class II beta-chain peptide prevents diabetes in nonobese diabetic mice.

P Chaturvedi1, B Agrawal, M Zechel, E Lee-Chan, B Singh.   

Abstract

We explored T cell responses to the self class II MHC (I-Ag7) beta-chain-derived peptides in diabetic and prediabetic nonobese diabetic (NOD) mice. We found that one of these immunodominant epitopes of the beta-chain of I-Ag7 molecule, peptide 54-76, could regulate autoimmunity leading to diabetes in NOD mice. T cells from prediabetic young NOD mice do not respond to the peptide 54-76, but T cells from diabetic NOD mice proliferated in response to this peptide. T cells from older nondiabetic mice or mice protected from diabetes do not respond to this peptide, suggesting a role for peptide 54-76-specific T cells in pathogenesis of diabetes. We show that this peptide is naturally processed and presented by the NOD APCs to self T cells. However, the peptide-specific T cells generated after immunization of young mice regulate autoimmunity in NOD mice by blocking the diabetogenic cells in adoptive transfer experiments. The NOD mice immunized with this peptide are protected from both spontaneous and cyclophosphamide-induced insulin-dependent diabetes mellitus. Immunization of young NOD mice with this peptide elicited T cell proliferation and production of Th2-type cytokines. In addition, immunization with this peptide induced peptide-specific Abs of IgG1 isotype that recognized native I-Ag7 molecule on the cell surface and inhibited the T cell proliferative responses. These results suggest that I-Abetag7(54-76) peptide-reactive T cells are involved in the pathogenesis of diabetes. However, immunization with this peptide at young age induces regulatory cells and the peptide-specific Abs that can modulate autoimmunity in NOD mice and prevent spontaneous and induced diabetes.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10843721     DOI: 10.4049/jimmunol.164.12.6610

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  7 in total

1.  CD8+ T cells control the TH phenotype of MBP-reactive CD4+ T cells in EAE mice.

Authors:  H Jiang; N S Braunstein; B Yu; R Winchester; L Chess
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-15       Impact factor: 11.205

2.  H2E-derived Ealpha52-68 peptide presented by H2Ab interferes with clonal deletion of autoreactive T cells in autoimmune thyroiditis.

Authors:  Nicholas K Brown; Daniel J McCormick; Chella S David; Yi-chi M Kong
Journal:  J Immunol       Date:  2008-05-15       Impact factor: 5.422

3.  Pancreatic NOD beta cells express MHC class II protein and the frequency of I-A(g7) mRNA-expressing beta cells strongly increases during progression to autoimmune diabetes.

Authors:  U Walter; T Toepfer; K E J Dittmar; K Kretschmer; J Lauber; S Weiss; G Servos; O Lechner; W A Scherbaum; S R Bornstein; H Von Boehmer; J Buer
Journal:  Diabetologia       Date:  2003-07-10       Impact factor: 10.122

4.  Delineating the role of the HLA-DR4 "shared epitope" in susceptibility versus resistance to develop arthritis.

Authors:  Veena Taneja; Marshall Behrens; Eati Basal; Josh Sparks; Marie M Griffiths; Harvinder Luthra; Chella S David
Journal:  J Immunol       Date:  2008-08-15       Impact factor: 5.422

Review 5.  Autoimmune thyroiditis: a model uniquely suited to probe regulatory T cell function.

Authors:  Yi-Chi M Kong; Gerald P Morris; Nicholas K Brown; Yan Yan; Jeffrey C Flynn; Chella S David
Journal:  J Autoimmun       Date:  2009-10-12       Impact factor: 7.094

6.  Intracellular MHC class II controls regulatory tolerance to allogeneic transplants.

Authors:  Christian LeGuern; Yoshinobu Akiyama; Sharon Germana; Katsunori Tanaka; Luis Fernandez; Yoshiko Iwamoto; Stuart Houser; Gilles Benichou
Journal:  J Immunol       Date:  2010-01-25       Impact factor: 5.422

7.  Immature Dendritic Cell Therapy Confers Durable Immune Modulation in an Antigen-Dependent and Antigen-Independent Manner in Nonobese Diabetic Mice.

Authors:  Jeannette Lo; Chang-Qing Xia; Ruihua Peng; Michael J Clare-Salzler
Journal:  J Immunol Res       Date:  2018-02-14       Impact factor: 4.818

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.